Comparative Pharmacology
Head-to-head clinical analysis: ADRUCIL versus METHOTREXATE SODIUM PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADRUCIL versus METHOTREXATE SODIUM PRESERVATIVE FREE.
ADRUCIL vs METHOTREXATE SODIUM PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorouracil (5-FU) is a pyrimidine analog that inhibits thymidylate synthase, interfering with DNA synthesis. It is metabolized to its active metabolites, which incorporate into RNA and DNA, causing cytotoxicity primarily in S-phase cells.
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), preventing the conversion of dihydrofolate to tetrahydrofolate, thereby interfering with DNA synthesis, repair, and cellular replication. It also inhibits thymidylate synthase and purine biosynthesis, and has immunosuppressive and anti-inflammatory effects mediated by adenosine release.
12 mg/kg IV bolus daily for 4 days, then if no toxicity, 6 mg/kg IV on days 6, 8, 10, and 12; or 15 mg/kg IV weekly; or 500-600 mg/m2 IV every 3-4 weeks.
15-25 mg once weekly orally or intramuscularly for rheumatoid arthritis; 50-75 mg/m2 once weekly intravenously for single-agent acute lymphoblastic leukemia maintenance; 50 mg/m2 intravenously every 2-4 weeks for ectopic pregnancy; 30-40 mg/m2 intravenously once weekly for psoriasis. Dosing varies by indication.
None Documented
None Documented
Biphasic elimination: initial t1/2α ~10-20 minutes, terminal t1/2β ~20-24 hours. Accumulation occurs with continuous infusion.
Terminal elimination half-life is 8-15 hours at standard doses; with high-dose therapy (>1 g/m²), half-life extends to 12-24 hours due to saturation of excretion pathways and potential third-space accumulation.
Primarily hepatic metabolism; renal excretion of metabolites accounts for ~60-80% of the dose. Unchanged fluorouracil excreted renally is <10%. Fecal excretion is minimal (<5%).
Primarily renal (80-90% excreted unchanged via glomerular filtration and active tubular secretion). Biliary/fecal elimination accounts for <10%.
Category C
Category D/X
Antimetabolite
Antimetabolite